TVTX vs. ANRO, ANNX, SLRN, TBPH, LRMR, NGNE, FULC, TRDA, PEPG, and CRBP
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Alto Neuroscience (ANRO), Annexon (ANNX), Acelyrin (SLRN), Theravance Biopharma (TBPH), Larimar Therapeutics (LRMR), Neurogene (NGNE), Fulcrum Therapeutics (FULC), Entrada Therapeutics (TRDA), PepGen (PEPG), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical preparations" industry.
Alto Neuroscience (NYSE:ANRO) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
In the previous week, Travere Therapeutics had 21 more articles in the media than Alto Neuroscience. MarketBeat recorded 22 mentions for Travere Therapeutics and 1 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.19 beat Travere Therapeutics' score of -1.00 indicating that Travere Therapeutics is being referred to more favorably in the news media.
Alto Neuroscience has a net margin of 0.00% compared to Alto Neuroscience's net margin of -56.02%. Travere Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.
Travere Therapeutics received 47 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
Alto Neuroscience has higher earnings, but lower revenue than Travere Therapeutics.
Alto Neuroscience presently has a consensus target price of $32.33, indicating a potential upside of 115.41%. Travere Therapeutics has a consensus target price of $16.69, indicating a potential upside of 147.29%. Given Alto Neuroscience's higher possible upside, analysts plainly believe Travere Therapeutics is more favorable than Alto Neuroscience.
Summary
Alto Neuroscience beats Travere Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
